{
  "task_id": "cw_104_task_a",
  "world_id": "world_104_neuro_cfo_pack",
  "task_name": "World 104 Task A  -  Post-Close QBO Reclass vs. Excel Model & CFO Board Deck Drift",
  "prompt": "Audit CortexMed Medical Systems' post-close QBO Trial Balance against the draft Excel financial model tabs (`cortexmed_gl_vs_excel_model_2026_09.xlsx`) and Slide 4 of the executive PowerPoint board deck (`cfo_board_deck_slide4_extract.txt`). Identify every figure in the Excel model and Slide 4 that drifted after the post-close adjusting journal entries, and compute the exact corrected figures.",
  "context_files": [
    "cortexmed_gl_vs_excel_model_2026_09.xlsx",
    "cfo_board_deck_slide4_extract.txt"
  ],
  "rubric": [
    {
      "id": "cw104a_01",
      "criterion_type": "Reasoning (numerical)",
      "description": "Identifies AJE-11 as a $42,600.00 reclassification of clinical contractor spend from 6400 G&A Professional Fees to 5300 Clinical COGS, increasing Clinical COGS from $304,800.00 to $347,400.00."
    },
    {
      "id": "cw104a_02",
      "criterion_type": "Reasoning (numerical)",
      "description": "Computes audited Gross Profit as $552,600.00 (61.40% Gross Margin) versus the stale $595,200.00 (66.13% Gross Margin) shown in Excel cell G14/G15 and Slide 4 (-$42,600.00 / -473 bps drift)."
    },
    {
      "id": "cw104a_03",
      "criterion_type": "Reasoning (numerical)",
      "description": "Identifies AJE-12 as capitalizing $15,000.00 of surgical jig tooling from 6450 R&D Supplies ($96,800.00 -> $81,800.00) to 1520 Fixed Assets."
    },
    {
      "id": "cw104a_04",
      "criterion_type": "Reasoning (numerical)",
      "description": "Computes audited Adjusted EBITDA as $184,200.00 (20.47% EBITDA margin) versus the stale $169,200.00 shown in Excel cell G28 and Slide 4 (+$15,000.00 drift)."
    },
    {
      "id": "cw104a_05",
      "criterion_type": "Reasoning (qualitative)",
      "description": "Explains why AJE-11 ($42,600.00 G&A to COGS) reduces Gross Profit by $42,600.00 but has $0.00 net impact on Adjusted EBITDA, whereas AJE-12 ($15,000.00 R&D Expense to CapEx) increases Adjusted EBITDA by $15,000.00."
    },
    {
      "id": "cw104a_06",
      "criterion_type": "Reasoning (qualitative)",
      "description": "Flags Slide 4 of `cfo_board_deck_slide4_extract.txt` as blocked from release until Gross Profit ($552,600.00), Gross Margin (61.40%), and Adjusted EBITDA ($184,200.00) are synchronized with the post-close QBO ledger."
    },
    {
      "id": "cw104a_07",
      "criterion_type": "Reasoning (numerical)",
      "description": "Reports post-close 6400 G&A Professional Fees as $106,000.00 and 6450 R&D Supplies as $81,800.00."
    },
    {
      "id": "cw104a_08",
      "criterion_type": "Reasoning (numerical)",
      "description": "Reports total post-close Operating Expenses (6400 G&A $106,000.00 + 6450 R&D $81,800.00 + Other OpEx $180,600.00) as $368,400.00."
    }
  ],
  "metadata": {
    "domain": "Fractional_CFO",
    "category": "Fractional CFO Board Pack & 3-Statement Modeling",
    "subcategory": "Post-Close GL Reclass to Excel Model / Board Deck Sync & Cash-Bridge History Guard",
    "estimated_completion_hours": 2.5
  },
  "license": "Level Personal, Academic & Non-Commercial Evaluation License v1.0 (Commercial Use Requires License from sam@levelcfo.com)",
  "commercial_licensing_contact": "sam@levelcfo.com",
  "canary_watermark_token": "LEVEL-IP-CANARY-9F4A-7C2E-PERSONAL-USE-ONLY-CONTACT-SAM-AT-LEVELCFO-COM"
}